

# **ZHANG Jinhua**

## **Chief Pharmacist, Associate Professor**

Department of Pharmacy, Fujian Maternity and Child Health Hospital  
College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics

Fujian Medical University  
Email: [pollyzhang2006@126.com](mailto:pollyzhang2006@126.com)

---

### **Qualifications**

PhD in Pharmacology, Fujian Medical University, China, 2009

Msc in Microbiology and Biochem Pharmaceutics, Fujian Medical University, 2006

BSc in Pharmaceutical Sciences, China Pharmaceutical University, China, 1998

### **Research Experience**

2022-Present Director, Department of Pharmacy, Fujian Maternity and Child Health Hospital

2010-2012 Visiting Assistant Researcher, Ronald Reagan UCLA Medical Center, Los Angeles

1998-2022 Clinical Pharmacists, Specializing in anticoagulant therapy,  
Department of Pharmacy, Fujian Medical University Union Hospital

### **Teaching Experience**

#### **Master's Supervisor**

Fujian Medical University, Fuzhou University (2013-present)

#### **Doctoral Supervisor**

Fujian University of Traditional Chinese Medicine (2024-present)

### **Training and Mentorship**

Trained 15 master's degree graduates and over 40 clinical pharmacists specializing in anticoagulant therapy.

Mentored students who received multiple awards, including national scholarships, first-class academic scholarships, and "Outstanding Graduate" awards.

## **Academic Leadership & Service**

2024 – Present

Member, Clinical Pharmacy Committee, Chinese Pharmaceutical Association

2018 – Present

Member, FIP Policy Committee, International Pharmaceutical Federation (FIP)

Supporting women and advocating for the responsible use of medicines

2017 – Present

Member, Patient Education Committee, Chinese Pharmacist Association

## **Editorial Experience**

### **Editor-in-Chief & Deputy Editor-in-Chief**

National Textbooks: *Clinical Pharmacy English Learning Tutoring* and *Clinical Pharmacy English*

### **Editor-in-Chief**

Professional Books: *Analysis of Typical Cases of Antithrombotic Drug Treatment*, *Essentials of Clinical Application of Heparin Drugs* and *Review of Antithrombotic and Hemostatic Drug Prescriptions*

### **Editorial Board Member (2015-Present)**

*China Pharmacist* and *Chinese Journal of Hospital Pharmacy*

Contributing to peer-review and editorial guidance for key publications in the field of clinical pharmacy and pharmacotherapy.

## **Awards & Recognitions**

Excellent Clinical Pharmacist (2017), Clinical Pharmacy Branch, Chinese Medical Association

Top 10 Young Clinical Pharmacists in China (2016), Journal of Medical Science

Star of Clinical Pharmacist Teaching (2016), Clinical Pharmacy Working Committee, Chinese Hospital Association

## **Research Interests**

**Anticoagulant Drug Management and Individualized Administration of Anticoagulants**

**Innovative Anticoagulation Clinic Setup:** Led the establishment of a novel anticoagulation clinic integrating online-to-offline strategies for enhanced management of thrombosis patients. Developed a specially-designed mobile application to facilitate anticoagulation management via patients' smartphones and tablets. The online platform complements offline anticoagulation services offered in our hospital clinic, improving therapeutic outcomes and patient compliance.

**Medicago Anticoagulation Online Club:** Initiated and established the Medicago anticoagulation online club, providing a platform for experienced patients to assist pharmacists in managing the care of new patients. This collaborative approach strengthens community-based patient support and ensures ongoing patient education and monitoring.

**Genomics and Pharmacodynamics Testing:** Pioneered the development of genomics, blood concentration, and pharmacodynamics testing methods for oral anticoagulants, including warfarin and direct oral anticoagulants (DOACs). These innovative approaches have enabled the creation of personalized anticoagulant therapy regimens for clinicians based on individual patient testing results, improving the precision of treatment protocols.

#### Research Publications (first author or corresponding author)

No	Title	Journal	JCR	IF	Year
1	Efficacy and safety of rivaroxaban in preventing venous thromboembolism in postoperative patients with gynecological malignancies: protocol for a randomised controlled open-label trial (G-alfalfa trial)	BMJ Open	Q3	2.4	2024
2	Global burden and attributable risk factors of inflammatory cardiomyopathy and myocarditis from 1990 to 2019	Arch Public Health	Q3	3.2	2024
3	Effects of intensive, targeted education by pharmacists on anticoagulant patients with atrial fibrillation: a multicentre randomized controlled trial from China	Eur J Cardiovasc Nurs	Q2	2.9	2024
4	Risk of bleeding, thrombosis and death among atrial fibrillation patients treated with oral anticoagulants across estimated glomerular filtration rates	Am J Cardiol	Q3	2.3	2024
5	Correlation between thrombocytopenia and adverse outcomes in patients with atrial fibrillation: a systematic review and meta-analysis	Front Cardiovasc Med	Q3	2.8	2024
6	The association between methionine synthase reductase c.66A>G variant and the risk of recurrent pregnancy loss: a systematic review and meta-analysis	J Gynecol Obstet Hum Reprod	Q4	1.7	2024

7	Cost-effectiveness analysis of lenvatinib plus pembrolizumab or everolimus as first-line treatment for advanced renal cell carcinoma	Cli Genitourin Cancer	Q3	2.3	2024
8	Effectiveness and safety study of formula containing probiotics, prebiotics, synbiotics on fullterm infants' growth - a systematic review and meta-analysis of randomized controlled study	Eur J Clin Nutr	Q3	3.6	2024
9	Application of alfalfa App in the management of oral anticoagulation in patients with atrial fibrillation: a multicenter randomized controlled trial	BMC Med Inform Decis Mak	Q3	3.3	2024
10	Signal mining of adverse reactions in the antiemetic drug ondansetron during pregnancy: A real-world analysis of the FDA adverse event reporting system (FAERS)	Expert Opin Drug Saf	Q3	3.0	2024
11	Proportion and risk factors for hospital-acquired venous thromboembolism in children: a systematic review and meta-analysis of data from 20 million individuals in 22 countries	Res Pract Thromb Haemost	Q3	3.4	2024
12	Web-based warfarin management (alfalfa app) versus traditional warfarin management: multicenter prospective cohort study	J Med Internet Res	Q2	5.8	2024
13	Construction of warfarin population pharmacokinetics and pharmacodynamics model in Han population based on Bayesian method	Sci Rep	Q2	3.8	2024
14	Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study	Front Pharmacol	Q2	4.4	2024
15	The alfalfa-inpatient-CAT assessment model: a thrombotic risk assessment model for inpatient cancer patients	BMC Cancer	Q2	3.4	2024
16	A new score for predicting intracranial hemorrhage in patients using antiplatelet drugs	Ann Hematol	Q3	3.0	2024
17	Negative association of GNRI with all-cause mortality in Chinese atrial fibrillation patients: a multicenter retrospective cohort study	Gerontology	Q3	3.1	2024
18	Stage IV ovarian cancer prognosis nomogram and analysis of racial differences: a study based on the SEER database	Heliyon	Q3	3.4	2024
19	Efficacy and safety of dabigatran and rivaroxaban in atrial fibrillation patients with impaired liver function: a multicenter retrospective cohort study	Eur J Clin Pharmacol	Q3	2.4	2024
20	Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis	Thromb J	Q4	2.6	2024

21	Network pharmacology analysis and molecular docking to identify the mechanism of Kuntai capsules: brief research on its action in premature ovarian insufficiency	J Cin P Pharm Ther	Q3	2.1	2024
22	Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis	Surg Endosc	Q2	2.4	2024
23	Risk factors for venous thromboembolism in a single pediatric intensive care unit in China	Thromb J	Q4	2.6	2024
24	Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis	World J Surg Oncol	Q3	2.5	2024
25	Association between high-mobility group box 1 levels and preeclampsia: a systematic review and meta-analysis	J Assist Reprod Genet	Q3	3.2	2024
26	Safety and efficacy of direct oral anticoagulants in stroke prevention in patients with atriafibrillation complicated with anemia and/orthrombocytopenia: a retrospective cohort study	Thromb J	Q3	3.1	2023
27	Interpretable machine learning models for predicting venous thromboembolism in the intensive care unit: an analysis based on data from 207 centers	Crit Care	Q1	15.1	2023
28	Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH)for extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis	Surg Endosc Oher Interv Tech	Q2	3.1	2023
29	Association between high-mobility group box 1 levels and preeclampsia: a systematic review and meta-analysis	J Assist Reprod Genet	Q3	3.1	2023
30	New score for predicting thromboembolic events in patients with atrial fibrillation using direct oral anticoagulants from a multicenter real-world study in China	Blood Coagul Fibrinolysis	Q4	1.1	2023
31	Global, regional, and national burden of ischaemic heart disease and its trends, 1990-2019	Public Health	Q3	5.2	2023
32	Application of a warfarin dosing calculator to guide individualized dosing versus empirical adjustment after fixed dosing: a pilot study	Front Pharmacol	Q2	5.6	2023
33	Risk factors for anticoagulant-associated gastrointestinal hemorrhage: a systematic review and meta-analysis	Korean J Intern Med	Q3	2.4	2023

34	The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban 1 through concentrations and bleeding events in patients with non-valvular atrial fibrillation	Hum Genomics	Q3	4.5	2023
35	A new model (alfalfa-warfarin-GIB) for predicting the risk of major gastrointestinal bleeding in warfarin patients	Eur J Clin Pharmacol	Q3	2.9	2023
36	An instrument to measure atrial fibrillation knowledge in Chinese patients: validation of the Jessa atrial fibrillation knowledge questionnaire	Front Pharmacol	Q2	5.6	2023
37	Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis	Eur J Clin Pharmacol	Q3	2.9	2023
38	Comparison of the efficacy and safety of rivaroxaban and low molecular heparin in preventing venous thromboembolism in inpatient cancer patients	Ann Pharmacother	Q3	2.9	2023
39	Rheumatic heart disease burden, trends, and inequalities in Asia, 1990-2019	Global Health Action	Q3	2.6	2023
40	Global burden of cardiovascular disease attributable to metabolic risk factors, 1990-2019: an analysis of observational data from a 2019 global burden of disease study	BMJ Open	Q3	2.9	2023
41	Safety and efficacy of direct oral anticoagulation in patients with and without radiofrequency ablation of non-valvular atrial fibrillation: a multicenter retrospective cohort study	Thromb J	Q3	3.1	2023
42	Cindices and rivaroxaban concentrations	Ann Pharmacother	Q3	2.9	2023
43	Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with hypertension: a multicenter, retrospective cohort study	J Clin Pharmacol	Q4	2.9	2023
44	New score for predicting major bleeding in patients with atrial fibrillation using direct oral anticoagulants	Int J Cardiol	Q2	3.5	2023
45	Risk factors for thrombolysis-related intracranial hemorrhage: a systematic review and meta-analysis.	Thromb J	Q3	3.1	2023
46	Risk factors for anticoagulant-associated intracranial hemorrhage: a systematic review and meta-analysis	Neurocrit Care	Q3	3.5	2023
47	Effect of genotype on the pharmacokinetics and bleeding events of direct oral anticoagulants: a systematic review and meta-analysis	J Clin Pharmacol	Q4	2.9	2023

48	Population pharmacokinetic analysis for model-based therapeutic drug monitoring of tacrolimus in Chinese Han heart transplant patients	Eur J Drug Metab Pharmacokinet	Q4	1.9	2023
49	A new model to predict the risk of major gastrointestinal bleeding in patients on direct oral anticoagulants (dabigatran and rivaroxaban)	Br J Clin Pharmacol	Q3	3.4	2023
50	Off-label dose direct oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation: a new evidence of Asian dose	Inter J Cardiol	Q2	3.5	2023
51	Efficacy and adverse events of clopidogrel and ticagrelor in patients with cytochrome P450 2C19 gene deletion	Indian J Pharma Sci	Q4	0.5	2023
52	Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis	Support Care Cancer	Q2	3.1	2022
53	Effect of genotype on the pharmacokinetics and bleeding events of direct oral anticoagulants: a systematic review and meta-analysis	J Clin Pharmacol	Q3	2.9	2022
54	Off-label dose direct oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation: a new evidence of Asian dose	Int J Cardiol	Q3	4.0	2022
55	A new model to predict the risk of major gastrointestinal bleeding in patients on direct oral anticoagulants (dabigatran and rivaroxaban)	Br J Clin Pharmacol	Q2	3.7	2022
56	Risk of nonmajor bleeding upon use of direct oral anticoagulants for preventing and treating venous thromboembolism: a network meta-analysis	Vasc Med	Q3	4.7	2022
57	Global burden of rheumatic heart disease and its association with socioeconomic development status, 1990-2019	Eur J Pre Cardiol	Q2	8.5	2022
58	Risk factors for antiplatelet drug-associated intracranial hemorrhage: a systematic review and meta-analysis.	Neurol Sci	Q3	3.8	2022
59	Direct oral anticoagulants versus warfarin in nonvalvular atrial fibrillation patients with prior gastrointestinal bleeding: a network meta-analysis of real-world data.	Eur J Clin Pharmacol	Q3	3.1	2022
60	Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study	J Thromb Thrombolysis	Q4	5.2	2022
61	Population pharmacokinetics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation: a prospective multicenter study	Clin Pharmacokinet	Q2	5.6	2022

62	Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: a meta-analysis	Eur J Clin Pharmacol	Q2	3.7	2022
63	Comparison of predictive value of risk scores for gastrointestinal bleeding in antiplatelet therapy	Platelets	Q3	4.2	2022
64	Effects and mechanism of action of <i>Panax notoginseng</i> Saponins on the pharmacokinetics of warfarin	Eur J Drug Metab Pharmacokinet	Q4	2.6	2022
65	Correction to: Effects and Mechanism of Action of <i>Panax notoginseng</i> Saponins on the Pharmacokinetics of Warfarin	Eur J Drug Metab Pharmacokinet	Q4	2.6	2022
66	Association between body mass index and clinical outcomes in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants: a new piece of evidence on the obesity paradox from China	Cardiovasc Drugs Ther	Q3	3.9	2022
67	Changes in the gut microbiota may affect the clinical efficacy of oral anticoagulants	Front Pharmacol	Q2	6.0	2022
68	Editor's choice - Severe bleeding risks of direct oral anticoagulants in the prevention and treatment of venous thromboembolism: a network meta-analysis of randomised controlled trials	Eur J Vasc Endovasc Surg	Q2	6.4	2022
69	The bridge between ischemic stroke and gut microbes: short-chain fatty acids	Cell Mol Neurobiol	Q2	4.2	2022
70	Effect of traditional plus virtual reality rehabilitation on prognosis of stroke survivors: a systematic review and meta-analysis of randomized controlled trials	Am J Phys Med Rehabil	Q4	3.4	2022
71	Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials	J Neurol	Q2	6.9	2022
72	A smartphone application for remote adjustment of warfarin dose: development and usability study	Appl Nurs Res	Q4	1.8	2022
73	Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin	Eur J Clin Pharmacol	Q3	3.1	2022
74	Impact of mobile health and telehealth technology on medication adherence of stroke patients: a systematic review and meta-analysis of randomized controlled trials	Int J Clin Pharm	Q4	2.3	2022
75	Efficacy and safety of non-vitamin K antagonist oral anticoagulants combined with antiplatelet drugs for patients with peripheral artery disease: A systematic review and meta-analysis of randomized controlled trials	Vascular	Q4	1.1	2022



76	To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study	Eur J Clin Pharmacol	Q3	3.1	2022
77	Risk of intracranial hemorrhage caused by direct oral anticoagulants for stroke prevention in patients with atrial fibrillation (from a network meta-analysis of randomized controlled trials)	Am J Cardiol	Q3	3.1	2022
78	Is an antithrombotic strategy after transcatheter aortic valve implantation clearer now?	J Thromb Thrombolysis	Q4	5.2	2021
79	Severe bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention and treatment in patients with atrial fibrillation: a systematic review and network meta-analysis	Cardiovasc Drugs Ther	Q2	3.9	2021
80	The value of mobile health in improving breastfeeding outcomes among perinatal or postpartum women: systematic review and meta-analysis of randomized controlled trials	JMIR mHealth uHealth	Q2	4.9	2021
81	Effects of telemedicine and mHealth on systolic blood pressure management in stroke patients: systematic review and meta-analysis of randomized controlled trials	JMIR mHealth uHealth	Q2	4.9	2021
82	Efficacy of mobile health in patients with low back pain: systematic review and meta-analysis of randomized controlled trials	JMIR mHealth uHealth	Q2	4.9	2021
83	Effectiveness of the alfalfa App in warfarin therapy management for patients undergoing venous thrombosis prevention and treatment: cohort study	JMIR mHealth uHealth	Q2	4.9	2021
84	Comparison of clinical performance of four gastrointestinal bleeding risk scores in Chinese patients with atrial fibrillation receiving oral anticoagulants	J Thromb Thrombolysis	Q4	5.2	2021
85	A newscore for predicting acute gastrointestinal bleeding in patients administered oral antiplatelet drugs	Front Pharmacol	Q2	6.0	2021
86	Toxic epidermal necrolysis in a patient on atorvastatin therapy expressing human leukocyte antigen alleles: a case report	Medicine (Baltimore)	Q4	1.2	2021